文献速递糖尿病

以肠道微生物组为靶点的治疗对2型糖尿病患者的血糖参数、炎症标志物及肠道菌群的影响:随机对照试验的系统评价与Meta分析

Glucose Parameters, Inflammation Markers, and Gut Microbiota Changes of Gut Microbiome-Targeted Therapies in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本Meta分析纳入54项随机对照试验(60组、3390例2型糖尿病患者),评估肠道微生物组靶向治疗对血糖代谢、炎症因子和肠道菌群的影响。结果显示该治疗可小幅降低空腹血糖、餐后2小时血糖、空腹胰岛素、HbA1c和胰岛素抵抗指数,降低促炎因子并增加有益菌群,但存在异质性且长期数据有限。

要点

  • 肠道微生物组靶向治疗小幅降低2型糖尿病患者的空腹血糖、餐后血糖、空腹胰岛素、HbA1c及胰岛素抵抗指数。
  • 该治疗降低高敏C反应蛋白、肿瘤坏死因子α和脂多糖,并升高白细胞介素-10。
  • 放线菌门、乳杆菌属及干酪乳杆菌亚群的丰度增加。

核心结论

  • 肠道微生物组靶向治疗小幅改善2型糖尿病患者的血糖代谢参数、降低促炎细胞因子并富集有益微生物(如放线菌门、乳杆菌属),但异质性和有限的长期数据提示需要大规模随机对照试验。

研究设计与样本

  • 系统评价与Meta分析,检索4个数据库纳入54项随机对照试验,共60组、3390例2型糖尿病患者。
  • 按地区、治疗类型、益生菌菌株数、益生菌剂量、益生元剂量、治疗持续时间、平均年龄和基线体重指数进行亚组分析。

主要发现

  • 空腹血糖MD = -7.97 mg/dL(95% CI = -10.82, -5.12;P < .00001)。
  • 餐后2小时血糖MD = -43.30 mg/dL(95% CI = -75.83, -10.77;P = .009)。
  • 空腹胰岛素MD = -1.73 uU/mL(95% CI = -2.63, -0.84;P = .0001)。
  • HbA1c MD = -0.28%(95% CI = -0.39, -0.17;P < .00001)。
  • 胰岛素抵抗指数MD = -0.53(95% CI = -0.85, -0.20;P = .0002)。

关键数值与推荐

  • 高敏C反应蛋白、肿瘤坏死因子α和脂多糖水平降低,白细胞介素-10水平升高。
  • 放线菌门、乳杆菌属和干酪乳杆菌亚群丰度增加。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出存在异质性。
  • 原文指出长期数据有限,需要大规模随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This meta-analysis aims to summarize the effects of gut microbiome-targeted therapies (MTTs) on glucometabolic, inflammatory factors and gut microbiota in patients with type 2 diabetes mellitus (T2DM). METHODS: Four databases were searched for randomized controlled trials (RCTs) that included subjects with T2DM who received MTTs. All results were presented as standardized mean difference (SMD) or mean difference (MD) and 95% CIs. In addition, subgroup analyses were performed according to region, type of MTTs, number of probiotic strains, probiotics dose, prebiotics dose, duration of MTTs, mean age, and baseline body mass index. RESULTS: A total of 54 RCTs were included, encompassing 60 groups and 3390 subjects. Overall, MTTs intervention decreased fasting plasma glucose (MD = -7.97 mg/dL [95% CI = -10.82, -5.12]; P < .00001), 2-hour postprandial blood glucose (MD = -43.30 mg/dL [95% CI = -75.83, -10.77]; P = .009), fasting insulin (MD = -1.73 uU/mL [95% CI = -2.63, -0.84]; P = .0001), HbA1c (MD = -0.28%, [95% CI = -0.39, -0.17]; P < .00001), and homeostatic model assessment of insulin resistance (MD =-0.53 [95% CI = -0.85, -0.20]; P = .0002). Furthermore, MTTs supplementation reduced high-sensitivity C-reactive protein, tumor necrosis factor alpha, and lipopolysaccharides. Meanwhile, the levels of interleukin-10 were increased. Moreover, the abundance of Actinobacteria, Lactobacillus, and Lactobacillus casei subgroup increased. CONCLUSION: MTTs modestly improved glucometabolic parameters, reduced pro-inflammatory cytokines, and enriched beneficial microbes (eg, Actinobacteria, Lactobacillus) in subjects with T2DM. However, heterogeneity and limited long-term data highlight the need for large-scale RCTs.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zhou X, Zheng W, Kong W, et al. Glucose Parameters, Inflammation Markers, and Gut Microbiota Changes of Gut Microbiome-Targeted Therapies in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2025. PMID: 40489582. doi:10.1210/clinem/dgaf340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。